Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- MNI ResearchMNI Research
Actionable insight on monetary policy, balance sheet and inflation with focus on global issuance. Analysis on key political risk impacting the global markets.
- About Us
China has reached "final stage" in approving the use of BioNTech's mRNA COVID-19 vaccine in cooption with Shanghai-based Fosun Pharma, the Global Times reported citing an interview with the German company's CEO Ugur Şahin. The developer is evaluating combining mRNA vaccines with inactivated and adenovirus vector jabs as booster shots to stabilize antibody levels against the coronavirus, Sahin was cited as saying. BioNTech is expected to be the first foreign-developed COVID-19 vaccine that China will import to pave the way for mixed shots in sequential inoculation, the newspaper said citing Shao Yiming, leading physician-scientist and immunologist serving at the Chinese Center for Disease Control and Prevention.